Footnotes

Report - National Health Amendment (Pharmaceutical and Other Benefits-Cost Recovery) Bill 2008

[1]        Department of the Parliamentary Library, Bills Digest no. 125, 2007-08, National Health Amendment (Pharmaceutical and Other Benefits–Cost Recovery) Bill 2008, 6 June 2008, pp. 2-11; National Health Amendment (Pharmaceutical and Other benefits–Cost Recovery) Bill 2008, pp 3-4.

[2]        Department of the Parliamentary Library, Bills Digest no. 125, 2007-08, p. 3; Department of Health and Ageing (DoHA), Submission 10, p. 5.

[3]        Department of the Parliamentary Library, Bills Digest no. 125, 2007-08, pp. 2-3; DoHA, Submission 10, pp. 4-8.

[4]        Department of the Parliamentary Library, Bills Digest no. 125, 2007-08, pp. 3, 9; DoHA, Submission 10, pp. 3, 6.

[5]        Second Reading Speech, National Health Amendment (Pharmaceutical and Other Benefits–Cost Recovery) Bill 2008, p. 5.

[6]        Associate Professor Thomas Faunce, Submission 11, p. 3.

[7]        Professor Allan McLean, Submission 2, pp 6-8.

[8]        Professor Allan McLean, Submission 2, p. 6.

[9]        Mr Stephen Dellar, First Assistant Secretary (Acting), DoHA, Committee Hansard, 28 July 2008, p. 73.

[10]      Wyeth Australia, Submission 3, p. 6; Mr Will Delaat, Chairman, Medicines Australia, Committee Hansard, 28 July 2008, p. 49.

[11]      Mr Will Delaat, Medicines Australia, Committee Hansard, 28 July 2008, pp 54-55. See also Submission 3, Medicines Australia, Submission 7; AusBiotech, Submission 4.

[12]      DoHA, Submission 10, p. 11.

[13]      DoHA, Submission 10, p. 11.

[14]      Pharmacy Guild of Australia, Submission 9, p. 1.

[15]      Medicines Australia, Submission 7, p. 9.

[16]      Mr Will Delaat, Chairman, and Dr Brendan Shaw, Executive Director, Medicines Australia, Committee Hansard, 28 July 2008, p. 57.

[17]      Mr John Dowling, Pharmacy Guild of Australia, Committee Hansard, 28 July 2008, pp 14-17; Pharmacy Guild of Australia, Submission 9, p. 2.

[18]      Australian Medical Association (AMA), Submission 1, p. 3.

[19]      Mr John Dowling, Chairman, Health Economics Committee, Pharmacy Guild of Australia, Committee Hansard, 28 July 2008, pp 14-17.

[20]      AMA, Submission 1, p. 3. See also AMA, answers to questions on notice, 28 July 2008 (received 28 July 2008).

[21]      AMA, Submission 1, p. 1.

[22]      DoHA, Submission 10, p. 10.

[23]      Mr Stephen Dellar, DoHA, Committee Hansard, 28 July 2008, p. 63.

[24]      Wyeth Australia, Submission 3, p. 6; Mr Will Delaat, Medicines Australia, Committee Hansard, 28 July 2008, pp 4-6.

[25]      Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, p. 27.

[26]      Professor Shane Carney, Chair, Therapeutics Expert Advisory Group, Royal Australasian College of Physicians, Committee Hansard, 28 July 2008, pp 6-8 and 10-12; Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, p. 27; Professor Peter Ravenscroft, Specialist in Palliative Medicine, and Ms Donna Daniell, Chief Executive Officer, Palliative Care Australia, Committee Hansard, 28 July 2008, pp 40-47.

[27]      Professor Shane Carney, Royal Australasian College of Physicians, Committee Hansard, 28 July 2008, p. 7.

[28]      Professor Peter Ravenscroft, Palliative Care Australia, Committee Hansard, 28 July 2008, pp 40-42.

[29]      Professor Shane Carney, Royal Australasian College of Physicians, Committee Hansard, 28 July 2008, pp 7 and 11; Mr John Dowling, Pharmacy Guild of Australia, Committee Hansard, 28 July 2008, p. 16.

[30]      Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, p. 27.

[31]      Professor Peter Ravenscroft, Palliative Care Australia, Committee Hansard, 28 July 2008, p. 44; Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, pp 27-28; Mr Will Delaat, Mr Ian Chalmers and Dr Brendan Shaw, Medicines Australia, Committee Hansard, 28 July 2008, pp 53-54.

[32]      See Wyeth Australia, Submission 3, pp 3-5; Medicines Australia, Submission 7, pp 1 and 5-7; The Royal Australasian College of Physicians, Submission 8, p. 2.

[33]      Wyeth Australia, Submission 3, p. 5.

[34]      See Palliative Care Australia, Submission 6, p. 1; Medicines Australia, Submission 7, pp 1 and 5-7; The Royal Australasian College of Physicians, Submission 8, p. 2; Sanofi-Aventis Australia, Submission 13, p. 1.

[35]      Medicines Australia, Submission 7, pp 5-6; The Royal Australasian College of Physicians, Submission 8, p. 3.

[36]      Professor Peter Ravenscroft, Palliative Care Australia, Committee Hansard, 28 July 2008, p. 44.

[37]      Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, p. 32.

[38]      The Royal Australasian College of Physicians, Submission 8, p. 2; Wyeth Australia, Submission 3, p. 4; Mr John Dowling, Pharmacy Guild of Australia, Committee Hansard, 28 July 2008, pp 16-20; Mr Bruce Shaw and Professor Peter Ravenscroft, Palliative Care Australia, Committee Hansard, 28 July 2008, p. 44; Mr Ian Chalmers, Medicines Australia, Committee Hansard, 28 July 2008, p. 54; Senator Gary Humphries, Committee Hansard, 28 July 2008, p. 26.

[39]      Professor Peter Ravenscroft, Palliative Care Australia, Committee Hansard, 28 July 2008, p. 42.

[40]      DoHA, Submission 10, pp 4 and 10.

[41]      Mr Stephen Dellar, DoHA, Committee Hansard, 28 July 2008, p. 65.

[42]      Wyeth Australia, Submission 3, pp 7-8; Medicines Australia, Submission 7, p. 10.

[43]      Professor Shane Carney, Royal Australasian College of Physicians, Committee Hansard, 28 July 2008, pp 6 and 9; Professor Christopher Nordin, Submission 12, p. 1; Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, p. 31; Mr Will Delaat, and Dr Brendan Shaw, Medicines Australia, Committee Hansard, 28 July 2008, p. 57.

[44]      Associate Professor Thomas Faunce, Submission 11, p. 4; and Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, pp 23-24.

[45]      DoHA, Submission 10, p. 12.

[46]      Medicines Australia, Submission 7, pp 1 and 10-11; and Sanofi-Aventis Australia, Submission 13, p. 1.

[47]      Mr Ian Chalmers, Chief Executive, Medicines Australia, Committee Hansard, 28 July 2008, pp 50-51.

[48]      Medicines Australia, Submission 7, pp 1 and 10-11.

[49]      Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, p. 31; Mr Ian Chalmers, Medicines Australia, Committee Hansard, 28 July 2008, p. 50.

[50]      Medicines Australia, Submission 7, p. 8.

[51]      Wyeth Australia, Submission 3, p. 7; Medicines Australia, Submission 7, pp 7-8; Mr Ian Chalmers, Medicines Australia, Committee Hansard, 28 July 2008, p. 51.

[52]      Mr Will Delaat and Mr Ian Chalmers, Medicines Australia, Committee Hansard, 28 July 2008, pp 55-56.

[53]      Mrs Diana Macdonell, Assistant Secretary (Acting), and Mr Stephen Dellar, DoHA, Committee Hansard, 28 July 2008, p. 69.

[54]      Mr Stephen Dellar, DoHA, Committee Hansard, 28 July 2008, pp 69-70.

[55]      Mr Stephen Dellar, DoHA, Committee Hansard, 28 July 2008, p. 70.

[56]      Medicines Australia, Submission 7, p. 11.

[57]      Medicines Australia, Submission 7, p. 11.

[58]      Medicines Australia, Submission 7, p. 11; Mr John Dowling, Pharmacy Guild of Australia, Committee Hansard, 28 July 2008, p. 19.

[59]      Mr Stephen Dellar, DoHA, Committee Hansard, 28 July 2008, pp 60-62.

[60]      Medicines Australia, Submission 7, p. 10; Mr Will Delaat, Medicines Australia, Committee Hansard, 28 July 2008, p. 50.

[61]      DoHA, Submission 10, pp 12-13; Mr David Learmonth, Deputy Secretary, DoHA, Committee Hansard, 28 July 2008, p. 62.

[62]      Department of Finance and Administration, Australian Government Cost Recovery Guidelines, July 2005, Financial Management Guidance No. 4, p. 2.

[63]      Medicines Australia, Submission 7, p. 13; Wyeth Australia, Submission 3, p. 9; and Australian Medical Association (AMA), Submission 1, p. 2.

[64]      Department of Health and Ageing, National Medicines Policy, 2000, p. 1. See Medicines Australia, Submission 7, pp 13-14; Wyeth Australia, Submission 3, p. 9; and AMA, Submission 1, pp 2-4.

[65]      Medicines Australia, Submission 7, pp 8-9 and 14.

[66]      Associate Professor Thomas Faunce, Committee Hansard, 28 July 2008, pp 22 and 32-33.

[67]      AMA, Submission 1, p. 4; Department of Finance and Administration, Australian Government Cost Recovery Guidelines, July 2005, Financial Management Guidance No. 4, p. 30.

[68]      The Royal Australasian College of Physicians, Submission 8, p. 2; Wyeth Australia, Submission 3, p. 9.

[69]      Medicines Australia, Submission 7, p. 12.

[70]      Mr David Learmonth, DoHA, Committee Hansard, 28 July 2008, p. 63.

[71]      DoHA, Submission 10, pp 15-19.

Report - National Health Amendment (Pharmaceutical and Other Benefits-Cost Recovery) Bill 2008

[1]        Committee Hansard 28.7.08, p.CA11.

[2]        Committee Hansard 28.7.08, p.CA19.

[3]        Committee Hansard 28.7.08, pp.CA43-4.

[4]        See Odgers' Australian Senate Practice, 11^th edition, 2004, Delegated Legislation and Disallowance, pp.321-343.

[5]        Committee Hansard 28.7.08, pp.CA11-12.

[6]        Committee Hansard 28.7.08, pp.CA42, 45-6.

[7]        Committee Hansard 28.7.08, pp.CA51-2.

[8]        Ms Roxon, House of Representatives Hansard, 31.5.07, p.12.

[9]        Medicines Australia, Submission 7, Additional information dated 12.8.08, p.2.